127 related articles for article (PubMed ID: 8259037)
1. Changes of serum 2',5'-oligoadenylate synthetase activity during interferon treatment of chronic hepatitis C.
Solinas A; Cossu P; Poddighe P; Tocco A; Deplano A; Garrucciu G; Diana MS
Liver; 1993 Oct; 13(5):253-8. PubMed ID: 8259037
[TBL] [Abstract][Full Text] [Related]
2. 2',5'-Oligoadenylate synthetase activity as a responsive marker during interferon therapy for chronic hepatitis C.
Giannelli G; Antonelli G; Fera G; Dianzani F; Schiraldi O
J Interferon Res; 1993 Feb; 13(1):57-60. PubMed ID: 8454912
[TBL] [Abstract][Full Text] [Related]
3. Serum 2',5'-oligoadenylate synthetase concentrations in acute and chronic hepatitis C.
Yang PM; Wang JT; Chiang BL; Lai MY; Chen DS
J Formos Med Assoc; 1997 May; 96(5):314-9. PubMed ID: 9170817
[TBL] [Abstract][Full Text] [Related]
4. 2',5' Oligoadenylate synthetase activity in peripheral blood mononuclear cells and serum during interferon treatment of chronic non-A, non-B hepatitis.
Okuno T; Shindo M; Arai K; Matsumoto M; Takeda M; Kashima K; Sokawa Y
Gastroenterol Jpn; 1991 Oct; 26(5):603-10. PubMed ID: 1752391
[TBL] [Abstract][Full Text] [Related]
5. Effect of obesity on pharmacokinetics and biologic effect of interferon-alpha in hepatitis C.
Lam NP; Pitrak D; Speralakis R; Lau AH; Wiley TE; Layden TJ
Dig Dis Sci; 1997 Jan; 42(1):178-85. PubMed ID: 9009135
[TBL] [Abstract][Full Text] [Related]
6. Treatment of chronic hepatitis C by continuous subcutaneous infusion of interferon-alpha.
Carreño V; Tapia L; Ryff JC; Quiroga JA; Castillo I
J Med Virol; 1992 Jul; 37(3):215-9. PubMed ID: 1331310
[TBL] [Abstract][Full Text] [Related]
7. Indomethacin enhances serum 2'5'-oligoadenylate synthetase in patients with hepatitis B and C virus chronic active hepatitis.
Andreone P; Cursaro C; Gramenzi A; Buzzi A; Miniero R; Sprovieri G; Gasbarrini G
J Hepatol; 1994 Dec; 21(6):984-8. PubMed ID: 7699263
[TBL] [Abstract][Full Text] [Related]
8. Prolonged treatment (2 years) with different doses (3 versus 6 MU) of interferon alpha-2b for chronic hepatitis type C. Results of a multicenter randomized trial.
Saracco G; Borghesio E; Mesina P; Solinas A; Spezia C; Macor F; Gallo V; Chiandussi L; Donada C; Donadon V; Spirito F; Mangia A; Andriulli A; Verme G; Rizzetto M
J Hepatol; 1997 Jul; 27(1):56-62. PubMed ID: 9252074
[TBL] [Abstract][Full Text] [Related]
9. Serum levels of 2',5 oligoadenylate synthetase during interferon therapy in patients with B-cell chronic lymphocytic leukemia.
Musolino C; Grosso P; Alonci A; Allegra A; Orlando A; Cincotta M; Buda G; Squadrito G
Am J Hematol; 1993 May; 43(1):1-4. PubMed ID: 8317456
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, pharmacodynamics, and hepatitis C viral kinetics during antiviral therapy: the null responder.
Di Bisceglie AM; Fan X; Chambers T; Strinko J
J Med Virol; 2006 Apr; 78(4):446-51. PubMed ID: 16566033
[TBL] [Abstract][Full Text] [Related]
11. Induction of 2'-5' oligoadenylate synthetase during interferon treatment of chronic myelogenous leukemia.
Moritz T; Weissmann B; Grünewald B; Hust H; Kummer G; Niederle N
Mol Biother; 1992 Jun; 4(2):97-102. PubMed ID: 1381190
[TBL] [Abstract][Full Text] [Related]
12. Activity of the interferon-induced 2',5'-oligoadenylate synthetase in patients with chronic hepatitis C.
Pawlotsky JM; Hovanessian A; Roudot-Thoraval F; Lebon P; Robert N; Bouvier M; Babany G; Duval J; Dhumeaux D
J Interferon Cytokine Res; 1995 Oct; 15(10):857-62. PubMed ID: 8564707
[TBL] [Abstract][Full Text] [Related]
13. Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: a randomized multicenter trial. Hepatitis Interventional Therapy Group.
Lindsay KL; Davis GL; Schiff ER; Bodenheimer HC; Balart LA; Dienstag JL; Perrillo RP; Tamburro CH; Goff JS; Everson GT; Silva M; Katkov WN; Goodman Z; Lau JY; Maertens G; Gogate J; Sanghvi B; Albrecht J
Hepatology; 1996 Nov; 24(5):1034-40. PubMed ID: 8903371
[TBL] [Abstract][Full Text] [Related]
14. Alpha interferon in the treatment of chronic hepatitis C infection in thalassaemia major.
Donohue SM; Wonke B; Hoffbrand AV; Reittie J; Ganeshaguru K; Scheuer PJ; Brown D; Dusheiko G
Br J Haematol; 1993 Mar; 83(3):491-7. PubMed ID: 8387324
[TBL] [Abstract][Full Text] [Related]
15. Therapy of active chronic hepatitis with recombinant alpha 2b-interferon: an 18 month follow-up.
Bresci G; Parisi G; Banti S; Bertoni M
Eur J Med; 1993; 2(6):349-52. PubMed ID: 8252180
[TBL] [Abstract][Full Text] [Related]
16. Effect of alpha interferon (IFN-alpha) on 2'-5' oligoadenylate synthetase activity in peripheral blood mononuclear cells of patients with chronic hepatitis C: relationship to the antiviral effect of IFN-alpha.
Pawlotsky JM; Hovanessian AG; Roudot-Thoraval F; Robert N; Bouvier M; Babany G; Duval J; Dhumeaux D
Antimicrob Agents Chemother; 1996 Feb; 40(2):320-4. PubMed ID: 8834873
[TBL] [Abstract][Full Text] [Related]
17. Treatment of chronic hepatitis C with high-dose interferon alpha-2b. A multicenter study.
Iino S; Hino K; Kuroki T; Suzuki H; Yamamoto S
Dig Dis Sci; 1993 Apr; 38(4):612-8. PubMed ID: 8384980
[TBL] [Abstract][Full Text] [Related]
18. Interferon alfa treatment of chronic hepatitis B: randomized trial in a predominantly homosexual male population.
Wong DK; Yim C; Naylor CD; Chen E; Sherman M; Vas S; Wanless IR; Read S; Li H; Heathcote EJ
Gastroenterology; 1995 Jan; 108(1):165-71. PubMed ID: 7806038
[TBL] [Abstract][Full Text] [Related]
19. Effect of interferon treatment on serum 2',5'-oligoadenylate synthetase levels in hepatitis C-infected patients.
Murashima S; Kumashiro R; Ide T; Miyajima I; Hino T; Koga Y; Ishii K; Ueno T; Sakisaka S; Sata M
J Med Virol; 2000 Oct; 62(2):185-90. PubMed ID: 11002247
[TBL] [Abstract][Full Text] [Related]
20. Effects of therapy with interferon-alpha on peripheral blood lymphocyte subsets and NK activity in patients with chronic hepatitis C.
Appasamy R; Bryant J; Hassanein T; Van Thiel DH; Whiteside TL
Clin Immunol Immunopathol; 1994 Dec; 73(3):350-7. PubMed ID: 7955564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
